Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CKS1B | P61024 | 1/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1781229 | 0.83 | L3MBTL1 (0.56) | L3MBTL1PTGS2PTGS1CYP11B1CYP11B2 | |
| SCHEMBL13695902 | 0.80 | L3MBTL1 (0.44) | L3MBTL1SIGMAR1POLB | |
| SCHEMBL5410976 | 0.80 | PTGS2 (0.43) | L3MBTL1PTGS2PTGS1CYP11B1CYP11B2 | |
| SCHEMBL29291548 | 0.79 | KIT (0.45) | L3MBTL1 | |
| SCHEMBL16793649 | 0.78 | L3MBTL1 (0.44) | L3MBTL1CYP3A4POLB | |
| SCHEMBL260617 | 0.77 | L3MBTL1 (0.55) | L3MBTL1GBA1PKMPOLBCYP2C19 | |
| SCHEMBL23147670 | 0.76 | L3MBTL1 (0.62) | L3MBTL1PTGS2PTGS1CYP11B1CYP11B2 | |
| SCHEMBL29721830 | 0.76 | L3MBTL1 (0.62) | L3MBTL1PTGS2PTGS1CYP11B1CYP11B2 | |
| SCHEMBL29722006 | 0.76 | L3MBTL1 (0.62) | L3MBTL1PTGS2CYP11B1CYP11B2GBA1 | |
| SCHEMBL23148129 | 0.76 | L3MBTL1 (0.62) | L3MBTL1PTGS2CYP11B1CYP11B2GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7259154-B2 | Anticancer agents; asthma; rhintis; vision disorders; skin disorders; antiarthritic agents; antiinflammatory agents; antiallergens | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-21 | — | — | US | disclosed |
| US-20040142947-A1 | Pyrrolopyrimidines | AVENTIS PHARMACEUTICALS, INC. | 2004-07-22 | — | — | US | disclosed |
| EP-1404676-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003000695-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142947-A1 | Pyrrolopyrimidines | DPYD, TYMP, PNPO | L3MBTL1 3350/4885PTGS2 1037/4885PTGS1 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.